Fig. 1From: Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trialTumor response with quizartinib monotherapy in a patient with GIST. Computed tomography scans of a patient with GIST demonstrated a 27% reduction in tumor burden with quizartinib monotherapy at the end of Cycle 1. Panels on the left represent baseline scans; panels on the right are from end of Cycle 1. GIST gastrointestinal stromal tumorBack to article page